PureTech Health
- Company typePublic
- Founded2001
- HeadquartersBoston, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
PureTech Health firmographics
Firmographics- Name
- PureTech Health
- Legal name
- PureTech Health plc
- Website
- https://puretechhealth.com
- Company type
- Public
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
PureTech Health industry classification
Industry- Product category
- Clinical-Stage Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industries
- Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF), Pulmonary Hypertension & Rare Pulmonary Disease Therapies (HLAIAIAG)
Keywords
Where PureTech Health is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
PureTech Health business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure
Revenue model
- Licensing Royalties: PureTech receives royalties on approved products commercialized by partners. For Cobenfy (formerly KarXT), PureTech retains rights to 2% royalty on annual sales above $2 billion, in addition to milestone payments. Previously sold 3% royalty to Royalty Pharma on net sales up to $2 billion annually.
- Milestone Payments: PureTech receives milestone payments upon achievement of regulatory approvals and commercial sales milestones under agreements with partners like Royalty Pharma and Bristol Myers Squibb for Cobenfy.
- Founded Entity Equity: PureTech maintains significant equity positions in its Founded Entities (Celea Therapeutics, Gallop Oncology, Seaport Therapeutics) and benefits from their fundraising activities and potential future exits or IPOs.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
PureTech Health product offering
Product offeringCore offering
PureTech Health is a clinical-stage biopharmaceutical company that invents and develops novel therapeutics for serious diseases through a Founded Entity model. The company advances candidates such as Cobenfy (FDA-approved for schizophrenia), deupirfenidone (idiopathic pulmonary fibrosis), and LYT-200 (myeloid malignancies), leveraging proprietary platforms including Glyph (lymphatic oral delivery), deuteration chemistry, and anti-galectin-9 antibodies. Approved products are commercialized through partnerships with large pharmaceutical companies such as Bristol Myers Squibb.
Product overview
PureTech Health is a clinical-stage biotherapeutics company with a portfolio of therapeutic candidates at various stages of development. The company's Founded Entities include Seaport Therapeutics (advancing GlyphAllo, GlyphAgo, and Glyph2BLSD for neuropsychiatric disorders using the Glyph platform), Celea Therapeutics (advancing deupirfenidone for idiopathic pulmonary fibrosis), and Gallop Oncology (advancing LYT-200 for myeloid malignancies). PureTech also retains economic interests in Cobenfy, which was invented at PureTech and received FDA approval in September 2024 for schizophrenia.
Differentiator
Problem solved
Functional benefit
Brands
- Glyph: Platform technology that enables oral bioavailability and lymphatic transport of drugs
- GlyphAllo (SPT-300)
- GlyphAgo (SPT-320)
- Celea Therapeutics
- Gallop Oncology
Products and services
- Seaport Therapeutics
- Celea Therapeutics
- Cobenfy (KarXT)
- Gallop Oncology
- Deupirfenidone (LYT-100)
- LYT-200
- GlyphAllo (SPT-300)
- GlyphAgo (SPT-320)
- Glyph2BLSD (SPT-348)
Quantifiable outcome
- Deupirfenidone 825mg TID demonstrated 91 mL slower FVC decline vs placebo at 26 weeks (p=0.02)
- +3 more outcomes
Companies that use PureTech Health
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
PureTech Health technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
PureTech Health partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- UC DaviscoreCollaborative research with UC Davis for Phase 2 trial of LYT-300 (oral allopregnanolone) in treating Fragile X-associated Tremor/Ataxia Syndrome (FXTAS). Funded by up to $11.4 million from U.S. Department of Defense.
- Auspex Pharmaceuticals (Teva)corePureTech acquired deupirfenidone (LYT-100) from Auspex Pharmaceuticals (now wholly owned subsidiary of Teva Pharmaceuticals) in July 2019. Auspex pioneered deuteration technology which achieved first-ever FDA approval for a deuterated drug with Austedo.
- New York UniversitycoreCo-development partnership for LYT-200 (anti-galectin-9 monoclonal antibody). PureTech invented LYT-200 in conjunction with partners at NYU, leveraging early access to foundational research on galectin-9 before its publication in Nature Medicine.
- BeiGeneminorClinical trial and supply agreement to evaluate LYT-200 and tislelizumab in patients with difficult-to-treat solid tumors.
- Monash UniversitycoreLicensed the Glyph platform technology from Monash University and continued to refine it before housing it in Seaport Therapeutics. Collaboration includes ongoing research including Phase 2b BUOY-1 trial for GlyphAllo.
Scale indicators14 records
Recent moves10 records
Expansion highlights5 records
PureTech Health competitors and assessment
Company assessmentDirect peers
- Roivant Sciences: Roivant Sciences operates a virtually identical Vant/Founded Entity model, creating subsidiary companies to develop specific therapeutic candidates. Both companies specialize in taking validated pharmacology and applying targeted innovation to address unmet medical needs across multiple therapeutic areas.
- Royalty Pharma: Royalty Pharma is the largest dedicated pharmaceutical royalty buyer. PureTech's business model directly involves acquiring and monetizing royalty streams (e.g., Cobenfy royalties), making Royalty Pharma a direct comparable in how biotech royalty assets are valued and traded.
- BridgeBio Pharma: BridgeBio operates a multi-asset rare disease biotech model with multiple subsidiaries advancing parallel programs. Like PureTech, BridgeBio maintains a portfolio of clinical-stage assets across diverse therapeutic areas and pursues capital-efficient development through entity-level financings.
- Axsome Therapeutics: Axsome is a CNS specialty pharmaceutical company with FDA-approved therapies in depression and migraine. Like PureTech's Cobenfy (first new schizophrenia mechanism in 50 years), Axsome developed Auvelity as a novel mechanism in depression, representing comparable CNS specialty pharma innovation.
- Sage Therapeutics: Sage Therapeutics focused on neuropsychiatric therapies (depression, epilepsy) and was acquired by Biogen. PureTech's Seaport Therapeutics has overlapping neuropsychiatric focus on MDD and GAD, making Sage a directly comparable specialty CNS biotech.
- FibroGen: FibroGen developed pamrevlumab and roxadustat, with significant focus on idiopathic pulmonary fibrosis (IPF). PureTech's Celea Therapeutics with deupirfenidone targets the same IPF market, making FibroGen a direct comparator in pulmonary fibrosis drug development.
- Karuna Therapeutics: Karuna Therapeutics was PureTech's Founded Entity that developed Cobenfy (KarXT), which was acquired by Bristol Myers Squibb for $14 billion in March 2024. It serves as the historical template for PureTech's Founded Entity model in neuropsychiatric drug development.
- Galapagos NV: Galapagos is a specialty biotech focused on immunology and fibrosis with a similar multi-asset clinical pipeline. The company's work in fibrotic diseases (IPF) directly parallels Celea Therapeutics' deupirfenidone program, and Galapagos operates a comparable specialty pharma innovation model.
Broad incumbents
- BioMarin Pharmaceutical: BioMarin is a larger rare disease specialty pharmaceutical company with multiple Orphan Drug Designations and FDA-approved therapies. While broader in scope, BioMarin shares PureTech's strategy of targeting rare/specialty indications with multiple program-specific development approaches.
- Vertex Pharmaceuticals: Vertex is an established biopharmaceutical innovator with a strong track record of taking validated mechanisms and developing transformative therapies. PureTech's 6x industry-average clinical success rate and focus on serious diseases with high unmet need parallels Vertex's specialty innovation approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
PureTech Health social profiles
Digital presencePureTech Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
PureTech Health leadership team
Management profileNumber of profiles
Profiles8 records
PureTech Health subsidiaries and ownership
Company hierarchySubsidiaries4 records
PureTech Health funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PureTech Health M&A and investment
M&A and investmentM&A
Investments28 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PureTech Health
What does PureTech Health do?
PureTech Health is a clinical-stage biopharmaceutical company that invents and develops novel therapeutics for serious diseases through a Founded Entity model. The company advances candidates such as Cobenfy (FDA-approved for schizophrenia), deupirfenidone (idiopathic pulmonary fibrosis), and LYT-200 (myeloid malignancies), leveraging proprietary platforms including Glyph (lymphatic oral delivery), deuteration chemistry, and anti-galectin-9 antibodies. Approved products are commercialized through partnerships with large pharmaceutical companies such as Bristol Myers Squibb.
Is PureTech Health a public or private company?
PureTech Health is a public company. It is classified as public and is currently operating.
When was PureTech Health founded?
PureTech Health was founded in 2001. It employs 51 to 100 people.
Where is PureTech Health based?
PureTech Health is headquartered in Boston, United States, in the North America region.
How does PureTech Health make money?
Three revenue lines are on record. Licensing Royalties are the primary driver. The others are milestone Payments and founded Entity Equity.
Who are PureTech Health's main competitors?
Direct peers on record are Roivant Sciences, Royalty Pharma, BridgeBio Pharma, Axsome Therapeutics, Sage Therapeutics, FibroGen, Karuna Therapeutics and Galapagos NV. Broad incumbents are BioMarin Pharmaceutical and Vertex Pharmaceuticals.
Does PureTech Health have an API?
No public API is recorded for PureTech Health.
What industry is PureTech Health in?
PureTech Health's product category is Clinical-Stage Biopharmaceuticals. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.